Last reviewed · How we verify

NCT05316350

Withings ECG-app Study

Completed NA Last updated 20 March 2024
What this trial tests

NA trial testing Electrocardiogram recording in Atrial Fibrillation in 685 participants. Completed in 15 August 2023.

Timeline
15 July 2022
Primary endpoint
15 August 2023
15 August 2023

Quick facts

Lead sponsorWithings
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment685
Start date15 July 2022
Primary completion15 August 2023
Estimated completion15 August 2023
Sites10 locations across France, United States

Drugs / interventions tested

Conditions studied

Sponsor

Withings — full company profile →

Who can join

22 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the performance of Withings HWA10 with embedded Withings ECG-app in the automatic detection of atrial fibrillation

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Electrocardiogram recording

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Withings trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05316350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing